• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Canopy Growth, Avadel Pharmaceuticals And Other Big Stocks Moving Lower On Friday

    6/23/23 10:33:43 AM ET
    $AI
    $AVDL
    $CGC
    $CRCT
    Computer Software: Prepackaged Software
    Technology
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AI alert in real time by email

    U.S. stocks traded lower, with the Nasdaq Composite dropping around 100 points on Friday. Here are some big stocks recording losses in today’s session.

    • GSR II Meteora Acquisition Corp. (NASDAQ:GSRM) fell 26.4% to $7.66.
    • Virgin Galactic Holdings, Inc. (NYSE:SPCE) dropped 17.4% to $4.3950 after the company announced another at-the-market stock offering of $400 million to raise capital. The offering would be dilutive to shares.
    • Avadel Pharmaceuticals plc (NASDAQ:AVDL) dropped 12.4% to $13.35. Jazz Pharmaceuticals filed suit against the FDA for approving Avadel Pharmaceuticals Lumryz (sodium oxybate extended-release) for cataplexy or excessive daytime sleepiness in adult patients with narcolepsy.
    • Kingsoft Cloud Holdings Limited (NASDAQ:KC) declined 12.5% to $5.62.
    • Canopy Growth Corporation (NASDAQ:CGC) dipped 11.5% to $0.5313 as the company said FY23 net revenue dropped 21%.
    • Cricut, Inc. (NASDAQ:CRCT) fell 9.4% to $15.38.
    • Sarepta Therapeutics, Inc. (NASDAQ:SRPT) dropped 9.2% to $112.51. Evercore ISI Group downgraded Sarepta Therapeutics from Outperform to Neutral and announced a $139 price target. The FDA granted accelerated approval to closely watched Sarepta Therapeutics’ gene therapy, Elevidys, for Duchenne muscular dystrophy (DMD) in ambulatory pediatric patients aged 4 through 5 years with a confirmed mutation in the DMD gene.
    • C3.ai, Inc. (NYSE:AI) fell 8.7% to $34.14.
    • Diversified Healthcare Trust (NASDAQ:DHC) fell 8.7% to $1.77.
    • Nikola Corporation (NASDAQ:NKLA) dropped 7.5% to $1.2763. Nikola Motor Company tweeted "Early this morning behind our phoenix headquarters, a fire occurred which affected multiple battery electric trucks. no one has been injured....."
    • P3 Health Partners Inc. (NASDAQ:PIII) fell 7.4% to $3.40.
    • XPeng Inc. (NYSE:XPEV) dropped 7.3% to $9.79.
    • NIO Inc. (NYSE:NIO) fell 6.5% to $8.34.
    • Novonix Limited (NASDAQ:NVX) fell 5.4% to $2.7250.

     

    Read More: Dow Tumbles 250 Points; CarMax Posts Upbeat Results

    Get the next $AI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AI
    $AVDL
    $CGC
    $CRCT

    CompanyDatePrice TargetRatingAnalyst
    C3.ai Inc.
    $AI
    2/26/2026Mkt Outperform → Mkt Perform
    Citizens
    Kingsoft Cloud Holdings Limited
    $KC
    2/11/2026$15.60Neutral → Buy
    Goldman
    Sarepta Therapeutics Inc.
    $SRPT
    1/28/2026$20.00Equal Weight
    Barclays
    NIO Inc.
    $NIO
    1/15/2026$6.10Neutral → Outperform
    Macquarie
    Sarepta Therapeutics Inc.
    $SRPT
    12/9/2025$32.00Outperform
    Wedbush
    NIO Inc.
    $NIO
    11/25/2025Outperform → Neutral
    Macquarie
    XPeng Inc.
    $XPEV
    11/18/2025$29.00Neutral → Buy
    Daiwa Securities
    Diversified Healthcare Trust
    $DHC
    11/13/2025$5.00Underperform → Sector Perform
    RBC Capital Mkts
    More analyst ratings

    $AI
    $AVDL
    $CGC
    $CRCT
    SEC Filings

    View All

    SEC Form 6-K filed by NIO Inc.

    6-K - NIO Inc. (0001736541) (Filer)

    2/26/26 6:17:06 AM ET
    $NIO
    Auto Manufacturing
    Industrials

    SEC Form 6-K filed by NIO Inc.

    6-K - NIO Inc. (0001736541) (Filer)

    2/26/26 6:03:29 AM ET
    $NIO
    Auto Manufacturing
    Industrials

    SEC Form 20-F filed by NOVONIX Limited

    20-F - NOVONIX Ltd (0001859795) (Filer)

    2/25/26 9:17:49 PM ET
    $NVX
    Industrial Machinery/Components
    Miscellaneous

    $AI
    $AVDL
    $CGC
    $CRCT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Sarepta Therapeutics Announces Call for Applications for the 9th Annual Route 79, The Duchenne Scholarship Program

    – Applications for the 2026-2027 academic year will be accepted until May 15, 2026 – Scholarships will be awarded to up to 20 individuals living with Duchenne muscular dystrophy and up to five siblings of individuals living with Duchenne Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the official opening of Route 79, The Duchenne Scholarship Program for the 2026-2027 academic year. Academic scholarships of up to $5,000 will be awarded to as many as 20 individuals living with Duchenne muscular dystrophy and five siblings of individuals living with Duchenne. "Since this program began nine years ago, significant progr

    2/27/26 9:00:00 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cricut® Introduces the Next Generation of Creativity – Cricut Joy™ 2 and Cricut Explore® 5

    A Media Snippet accompanying this announcement is available by clicking on this link. SOUTH JORDAN, Utah, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Cricut®, Inc. (NASDAQ:CRCT) is making personalization easier than ever with the introduction of two next-generation cutting machines: Cricut Joy™ 2 and Cricut Explore® 5. These machines represent the start of a new era for Cricut users, including a smaller, modern machine design, a dramatically simplified, guided software experience, and all the tools and materials needed to get started right in the box. Introducing Cricut Joy 2: Big Creativity, Small FootprintCricut Joy 2 is the next iteration of Cricut's most compact cutting machine – it's perfec

    2/26/26 12:00:00 PM ET
    $CRCT
    Industrial Machinery/Components
    Technology

    C3 AI to Present at Two Investor Conferences on March 2, 2026

    C3 AI (NYSE:AI), the Enterprise AI application software company, today announced that C3 AI CEO Stephen Ehikian will participate in fireside chats at the following investor conferences: The Citizens Technology Conference in San Francisco, CA. The fireside chat is scheduled for Monday, March 2, 2026, at 9:00 am PT. The Morgan Stanley Technology, Media & Telecom Conference in San Francisco, CA. The fireside chat is scheduled for Monday, March 2, 2026, at 10:00 am PT. Interested parties will be able to watch replays of the webcasts, which will be accessible on the C3 AI Investor Relations website (ir.c3.ai) following the event. About C3.ai, Inc. C3 AI is the Enterprise AI applicat

    2/26/26 9:00:00 AM ET
    $AI
    Computer Software: Prepackaged Software
    Technology

    $AI
    $AVDL
    $CGC
    $CRCT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Bilotto Christopher J. bought $97,720 worth of Common Shares of Beneficial Interest (20,000 units at $4.89), increasing direct ownership by 8% to 266,285 units (SEC Form 4)

    4 - DIVERSIFIED HEALTHCARE TRUST (0001075415) (Issuer)

    12/16/25 4:44:03 PM ET
    $DHC
    Real Estate Investment Trusts
    Real Estate

    Chief Executive Officer Mongeau Luc bought $49,994 worth of shares (27,469 units at $1.82), increasing direct ownership by 3% to 812,368 units (SEC Form 4)

    4 - Canopy Growth Corp (0001737927) (Issuer)

    9/23/25 4:15:11 PM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Palczuk Linda bought $39,640 worth of Ordinary Shares (5,000 units at $7.93), increasing direct ownership by 8% to 67,900 units (SEC Form 4)

    4 - AVADEL PHARMACEUTICALS PLC (0001012477) (Issuer)

    1/22/25 4:13:34 PM ET
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AI
    $AVDL
    $CGC
    $CRCT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    C3.ai downgraded by Citizens

    Citizens downgraded C3.ai from Mkt Outperform to Mkt Perform

    2/26/26 7:10:22 AM ET
    $AI
    Computer Software: Prepackaged Software
    Technology

    Kingsoft Cloud upgraded by Goldman with a new price target

    Goldman upgraded Kingsoft Cloud from Neutral to Buy and set a new price target of $15.60

    2/11/26 7:42:03 AM ET
    $KC
    Computer Software: Prepackaged Software
    Technology

    Barclays resumed coverage on Sarepta Therapeutics with a new price target

    Barclays resumed coverage of Sarepta Therapeutics with a rating of Equal Weight and set a new price target of $20.00

    1/28/26 7:19:11 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AI
    $AVDL
    $CGC
    $CRCT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for AMONDYS 45 issued to SAREPTA THERAPS INC

    Submission status for SAREPTA THERAPS INC's drug AMONDYS 45 (SUPPL-8) with active ingredient CASIMERSEN has changed to 'Approval' on 07/11/2024. Application Category: NDA, Application Number: 213026, Application Classification: Labeling

    7/12/24 4:40:36 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    June 20, 2024 - FDA Expands Approval of Gene Therapy for Patients with Duchenne Muscular Dystrophy

    For Immediate Release: June 20, 2024 Today, the U.S. Food and Drug Administration expanded the approval of Elevidys (delandistrogene moxeparvovec-rokl), a gene therapy for the treatment of Duchenne muscular dystrophy (DMD) for ambulatory and non-ambulatory individuals 4 years of age and older with DMD with a confirmed mutation in the DMD gene.  Elevidys was previously approved under accelerated approval for amb

    6/20/24 5:24:42 PM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for VYONDYS 53 issued to SAREPTA THERAPS INC

    Submission status for SAREPTA THERAPS INC's drug VYONDYS 53 (SUPPL-11) with active ingredient GOLODIRSEN has changed to 'Approval' on 06/04/2024. Application Category: NDA, Application Number: 211970, Application Classification: Labeling

    6/5/24 4:41:31 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AI
    $AVDL
    $CGC
    $CRCT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Ashish Arora sold $821,664 worth of shares (180,000 units at $4.56), decreasing direct ownership by 5% to 3,798,453 units (SEC Form 4)

    4 - Cricut, Inc. (0001828962) (Issuer)

    2/23/26 6:01:51 PM ET
    $CRCT
    Industrial Machinery/Components
    Technology

    Chief Financial Officer Shill Kimball C covered exercise/tax liability with 62,029 shares, decreasing direct ownership by 4% to 1,374,871 units (SEC Form 4)

    4 - Cricut, Inc. (0001828962) (Issuer)

    2/19/26 4:10:23 PM ET
    $CRCT
    Industrial Machinery/Components
    Technology

    Chief Executive Officer Ashish Arora covered exercise/tax liability with 265,206 shares, decreasing direct ownership by 6% to 3,978,453 units (SEC Form 4)

    4 - Cricut, Inc. (0001828962) (Issuer)

    2/19/26 4:08:22 PM ET
    $CRCT
    Industrial Machinery/Components
    Technology

    $AI
    $AVDL
    $CGC
    $CRCT
    Leadership Updates

    Live Leadership Updates

    View All

    Canopy Growth to Acquire MTL Cannabis; Transaction Expected to Create Canada's Leading Medical Cannabis Business and Enhance Capacity to Serve Growing International Demand

    This news release constitutes a "designated news release" for the purposes of Canopy Growth's prospectus supplement dated August 29, 2025 to its short form base shelf prospectus dated June 5, 2024 All financial amounts in this press release are expressed in Canadian dollars. Highly accretive business combination expected to generate significant run-rate synergies of approximately $10 million within 18 months Strengthens Canopy Growth's presence in Québec with an opportunity to expand national distribution of MTL's high-quality, budtender-recommended product portfolio2 MTL's core management team is expected to join Canopy Growth to drive cultivation excellence and enhance the Company's p

    12/15/25 7:00:00 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Mike Clayville Joins C3 AI Board of Directors

    C3 AI (NYSE:AI), the Enterprise AI application software company, today announced the appointment of Mike Clayville to its board of directors, effective November 9, 2025. Mr. Clayville brings over 30 years of enterprise software and cloud infrastructure expertise. Most recently, he served as Chief Customer Officer at Stripe. Before Stripe, he led global commercial sales at Amazon Web Services, overseeing operations serving millions of customers across 170 countries. Earlier in his career, Mr. Clayville held senior leadership roles at VMware, BEA Systems, Tivoli Systems, and IBM, leading large-scale digital transformation initiatives. "Mike has spent his career helping companies grow an

    11/13/25 9:00:00 AM ET
    $AI
    Computer Software: Prepackaged Software
    Technology

    Canopy Growth Announces Results of Annual General and Special Meeting of Shareholders

    Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC), a world-leading cannabis company dedicated to unleashing the power of cannabis to improve lives, is pleased to announce today the voting results from its Annual General and Special Meeting of Shareholders convened on September 26, 2025 and adjourned to, and reconvened on, October 10, 2025 (the "Meeting"). All of the matters put forward before the Company's shareholders for consideration and approval, as set out in the Company's definitive proxy statement dated August 7, 2025 (the "Proxy Statement"), were approved by the requisite number of votes cast at the Meeting, as further detailed below. Each of t

    10/14/25 7:00:00 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    $AI
    $AVDL
    $CGC
    $CRCT
    Financials

    Live finance-specific insights

    View All

    NIO Inc. to Report Unaudited Fourth Quarter and Full Year 2025 Financial Results on Tuesday, March 10, 2026

    SHANGHAI, Feb. 26, 2026 (GLOBE NEWSWIRE) -- NIO Inc. (NYSE:NIO, HKEX: 9866, SGX: NIO)) ("NIO" or the "Company"), a pioneer and a leading company in the global smart electric vehicle market, today announced that it will report its unaudited financial results for the fourth quarter and full year ended December 31, 2025 on Tuesday, March 10, 2026, before the open of the U.S. markets. The Company's management will host an earnings conference call at 8:00 AM U.S. Eastern Time on March 10, 2026 (8:00 PM Beijing/Hong Kong/Singapore Time on March 10, 2026). A live and archived webcast of the conference call will be available on the Company's investor relations website at https://ir.nio.com/news-

    2/26/26 4:35:00 AM ET
    $NIO
    Auto Manufacturing
    Industrials

    Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Developments

    Net product revenues for the full year 2025 totaled $1,864.3 million, consisting of $965.6 million of PMO net product revenue and $898.7 million of ELEVIDYS net product revenue Net product revenues for the fourth quarter 2025 totaled $369.6 million, consisting of $259.2 million of PMO net product revenue and $110.4 million of ELEVIDYS net product revenue Following refinancing of 2027 notes and corporate restructuring, overall financial position and capital structure strengthened to support full investment in our pipeline and marketed therapies Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for

    2/25/26 4:05:00 PM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Diversified Healthcare Trust Announces Fourth Quarter 2025 Results

    Provides Full Year 2026 Financial Guidance Diversified Healthcare Trust (NASDAQ:DHC) today announced its financial results for the quarter ended December 31, 2025 and provided full year 2026 financial guidance, which can be found at the Quarterly Reports section of DHC's website at https://www.dhcreit.com/investors/financial-information/quarterly/default.aspx. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260223198867/en/ A conference call to discuss DHC's fourth quarter 2025 financial results will be held on Tuesday, February 24, 2026 at 10:00 a.m. Eastern Time. The conference call may be accessed by dialing (877) 329-4297 o

    2/23/26 4:15:00 PM ET
    $DHC
    $RMR
    Real Estate Investment Trusts
    Real Estate
    Professional Services
    Consumer Discretionary

    $AI
    $AVDL
    $CGC
    $CRCT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by C3.ai Inc.

    SC 13G/A - C3.ai, Inc. (0001577526) (Subject)

    11/14/24 5:03:49 PM ET
    $AI
    Computer Software: Prepackaged Software
    Technology

    SEC Form SC 13G filed by P3 Health Partners Inc.

    SC 13G - P3 Health Partners Inc. (0001832511) (Subject)

    11/14/24 4:33:46 PM ET
    $PIII
    Medical/Nursing Services
    Health Care

    Amendment: SEC Form SC 13G/A filed by Avadel Pharmaceuticals plc

    SC 13G/A - AVADEL PHARMACEUTICALS PLC (0001012477) (Subject)

    11/14/24 6:10:30 AM ET
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care